Skip to main content
Top
Published in: BMC Public Health 1/2017

Open Access 01-12-2017 | Research article

Estimating the number of people who inject drugs in Australia

Authors: Sarah Larney, Matthew Hickman, Rebecca Guy, Jason Grebely, Gregory J. Dore, Richard T. Gray, Carolyn A. Day, Jo Kimber, Louisa Degenhardt

Published in: BMC Public Health | Issue 1/2017

Login to get access

Abstract

Background

Injecting drug use is associated with considerable morbidity and mortality. Estimates of the size of the population of people who inject drugs are critical to inform service planning and estimate disease burden due to injecting drug use. We aimed to estimate the size of the population of people who inject drugs in Australia.

Methods

We applied a multiplier method which used benchmark data (number of people in opioid substitution therapy (OST) on a snapshot day in 2014) and multiplied it by a factor derived from the prevalence of current OST among people who inject drugs participating in the Australian Needle and Syringe Program Survey in 2014. Estimates of the total population of people who inject drugs were calculated in each state and territory and summed to produce a national estimate. We used the sex and age group distribution seen in datasets relating to people who inject drugs to derive sex- and age-stratified estimates, and calculated prevalence per 1000 population.

Results

Between 68,000 and 118,000 people aged 15–64 years inject drugs in Australia. The population prevalence of injecting drug use was 6.0 (lower and upper uncertainty intervals of 4.3 and 7.6) per 1000 people aged 15–64 years. Injecting drug use was more common among men than women, and most common among those aged 35–44 years. Comparison of expected drug-related deaths based on these estimates to actual deaths suggest that these figures may be underestimates.

Conclusions

These are the first indirect prevalence estimates of injecting drug use in Australia in over a decade. This work has identified that there are limited data available to inform estimates of this population. These estimates can be used as a basis for further work estimating injecting drug use in Australia.
Appendix
Available only for authorised users
Literature
1.
go back to reference Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, Cowie B, Hall WD, Strang J, Whiteford H, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(12):1385–98.CrossRefPubMed Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, Cowie B, Hall WD, Strang J, Whiteford H, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(12):1385–98.CrossRefPubMed
2.
go back to reference Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: A systematic review and meta-analysis. Bull World Health Organ. 2013;91:102–23.CrossRefPubMedPubMedCentral Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: A systematic review and meta-analysis. Bull World Health Organ. 2013;91:102–23.CrossRefPubMedPubMedCentral
3.
go back to reference Abdul-Quader AS, Baughman AL, Hladik W. Estimating the size of key populations: Current status and future possibilities. Curr Opin HIV AIDS. 2014;9:107–14.CrossRefPubMed Abdul-Quader AS, Baughman AL, Hladik W. Estimating the size of key populations: Current status and future possibilities. Curr Opin HIV AIDS. 2014;9:107–14.CrossRefPubMed
4.
go back to reference World Health Organization. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: World Health Organization; 2012. World Health Organization. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: World Health Organization; 2012.
5.
go back to reference Law MG. Modelling the hepatitis C virus epidemic in Australia. J Gastroenterol Hepatol. 1999;14:1100–7.CrossRefPubMed Law MG. Modelling the hepatitis C virus epidemic in Australia. J Gastroenterol Hepatol. 1999;14:1100–7.CrossRefPubMed
6.
go back to reference Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol. 2003;32(5):717–24.CrossRefPubMed Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol. 2003;32(5):717–24.CrossRefPubMed
7.
go back to reference Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007;91(2–3):228–35.CrossRefPubMed Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007;91(2–3):228–35.CrossRefPubMed
8.
go back to reference Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: A consensus statement. Med J Aust. 2016;204:268–72.CrossRefPubMed Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: A consensus statement. Med J Aust. 2016;204:268–72.CrossRefPubMed
9.
go back to reference The Kirby Institute. Uptake of new treatment for chronic hepatitis C during March 2016. In: Monitoring hepatitis C treatment uptake in Australia. vol. 1. Sydney: The Kirby Institute; 2016. The Kirby Institute. Uptake of new treatment for chronic hepatitis C during March 2016. In: Monitoring hepatitis C treatment uptake in Australia. vol. 1. Sydney: The Kirby Institute; 2016.
10.
go back to reference Hickman M, Taylor C. Indirect methods to estimate prevalence. In: Sloboda Z, editor. Future work and conclusions. edn ed. USA: Springer Science + Business Media; 2005. p. 113–31. Hickman M, Taylor C. Indirect methods to estimate prevalence. In: Sloboda Z, editor. Future work and conclusions. edn ed. USA: Springer Science + Business Media; 2005. p. 113–31.
11.
go back to reference Iversen J, Maher L. Australian NSP Survey 20 Year National Data Report 1995–2014. Kirby Institute, UNSW Australia: Sydney; 2015. Iversen J, Maher L. Australian NSP Survey 20 Year National Data Report 1995–2014. Kirby Institute, UNSW Australia: Sydney; 2015.
12.
go back to reference AIHW. National Opioid Pharmacotherapy Statistical Annual Data (NOPSAD) Collection. Australian Institute of Health and Welfare: Canberra; 2015. AIHW. National Opioid Pharmacotherapy Statistical Annual Data (NOPSAD) Collection. Australian Institute of Health and Welfare: Canberra; 2015.
13.
go back to reference Larance B, Mattick RP, Ali R, Lintzeris N, Jenkinson R, White N, Kihas I, Cassidy R, Degenhardt L. Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. Drug Alcohol Rev. 2016;35:83–91.CrossRef Larance B, Mattick RP, Ali R, Lintzeris N, Jenkinson R, White N, Kihas I, Cassidy R, Degenhardt L. Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. Drug Alcohol Rev. 2016;35:83–91.CrossRef
14.
go back to reference Australian Bureau of Statistics. 3235.0 Population by age and sex, regions of Australia. Canberra: Australian Bureau of Statistics; 2015. Australian Bureau of Statistics. 3235.0 Population by age and sex, regions of Australia. Canberra: Australian Bureau of Statistics; 2015.
15.
go back to reference Nambiar D, Agius PA, Stoové M, Hickman M, Dietze P. Mortality in the Melbourne injecting drug user cohort study (MIX). Harm Reduction J. 2015;12:55.CrossRef Nambiar D, Agius PA, Stoové M, Hickman M, Dietze P. Mortality in the Melbourne injecting drug user cohort study (MIX). Harm Reduction J. 2015;12:55.CrossRef
16.
go back to reference Australian Bureau of Statistics, Customised report. 2016. Australian Bureau of Statistics, Customised report. 2016.
17.
go back to reference Roxburgh A, Breen C. Accidental drug-induced deaths due to opioids in Australia 2012. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2016. Roxburgh A, Breen C. Accidental drug-induced deaths due to opioids in Australia 2012. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2016.
18.
go back to reference Quinn B, Stoové M, Papanstasiou C, Dietze P. Methamphetamine use in Melbourne Australia: Baseline characteristics of a prospective methamphetamine-using cohort and correlates of methamphetamine dependence. J Subst Use. 2013;18:349–62.CrossRef Quinn B, Stoové M, Papanstasiou C, Dietze P. Methamphetamine use in Melbourne Australia: Baseline characteristics of a prospective methamphetamine-using cohort and correlates of methamphetamine dependence. J Subst Use. 2013;18:349–62.CrossRef
19.
go back to reference McKetin R, Ross J, Kelly E, Baker A, Lee N, Lubman DI, Mattick R. Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants. Drug Alcohol Rev. 2008;27:277–85.CrossRefPubMed McKetin R, Ross J, Kelly E, Baker A, Lee N, Lubman DI, Mattick R. Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants. Drug Alcohol Rev. 2008;27:277–85.CrossRefPubMed
20.
go back to reference Iversen J, Linsen S, Kwon JA, Maher L. Needle Syringe Program National Minimum Data Collection. Kirby Institute, UNSW Sydney: Sydney; 2016. Iversen J, Linsen S, Kwon JA, Maher L. Needle Syringe Program National Minimum Data Collection. Kirby Institute, UNSW Sydney: Sydney; 2016.
21.
go back to reference Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham E, Trickey AJ, Dumchev K, et al. Sociodemographic characteristics and prevalence of HIV, hepatitis B virus, and hepatitis C virus in people who inject drugs worldwide: A multistage systematic review. The Lancet Global Health (in press). Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham E, Trickey AJ, Dumchev K, et al. Sociodemographic characteristics and prevalence of HIV, hepatitis B virus, and hepatitis C virus in people who inject drugs worldwide: A multistage systematic review. The Lancet Global Health (in press).
22.
go back to reference Darke S, Marel C, Mills KL, Ross J, Slade T, Teesson M. Years of potential life list amongst heroin users in the Australian Treatment Outcome Study. Drug Alcohol Depend. 2016;162:206–10.CrossRefPubMed Darke S, Marel C, Mills KL, Ross J, Slade T, Teesson M. Years of potential life list amongst heroin users in the Australian Treatment Outcome Study. Drug Alcohol Depend. 2016;162:206–10.CrossRefPubMed
23.
go back to reference Hickman M, De Angelis D, Jones HE, Harris R, Welton N, Ades AE. Multiple parameter evidence synthesis - a potential solution for when information on drug use and harm is in conflict. Addiction. 2013;108:1529–31.CrossRefPubMed Hickman M, De Angelis D, Jones HE, Harris R, Welton N, Ades AE. Multiple parameter evidence synthesis - a potential solution for when information on drug use and harm is in conflict. Addiction. 2013;108:1529–31.CrossRefPubMed
Metadata
Title
Estimating the number of people who inject drugs in Australia
Authors
Sarah Larney
Matthew Hickman
Rebecca Guy
Jason Grebely
Gregory J. Dore
Richard T. Gray
Carolyn A. Day
Jo Kimber
Louisa Degenhardt
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2017
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-017-4785-7

Other articles of this Issue 1/2017

BMC Public Health 1/2017 Go to the issue